通过RNAi和干细胞来进行筛选打破基因组新药开发的僵局

进行基因组新药的研发不一定就能发明新药。美国大型企业和国立卫生研究院（NIH）的生物技术相关预算一方面在迅速上升：另一方面美国食品与药物管理局批准的新药数量却在减少。解决上述问题的秘诀就在于RNAi和干细胞组合起来的高通量筛选（11ighthroughputscreening，HTS）技术。[第一段]     

关注微生物来源的新药开发

自然界中微生物的多样性及其代谢产物的多样性,提供了发现新药(以及先导化合物)的不竭动力。随着生命科学的发展,尤其是随着分子生物学技术的发展和应用,使得以微生物为源泉的新药研发有了更多的支持,微生物药物的研究越来越受到国内外的重视。     

基因组解析与新药开发

由于ＤＮＡ微阵列技术 ,基因表达的解析已成为可能 ,个体基因差异也正在被发现 ,并产生了一个新的领域———药物基因组学 ,药物开发的模式发生了根本性的改变。基因组解析将为许多新药开发提供目标 ,新的药物筛选系统正在形成 ,基于新的作用功能的先导化合物正在被发现 ,利用ＤＮＡ微阵列技术而实施药理学与安全性评价 ,从基因序列开始对药物标靶的立体构造进行预测 ,从而选择最优秀的化合物。对于临床试验 ,诊断患者的基因多态性 ,筛选最合适的试验人群 ,提高新药的通过率 ,根据个体的基因差异使给药个体化 ,减少副作用 ,加速新药的开发。…     

中国昆虫资源研究开发现状

昆虫具有种类多、数量大等特点,是一类非常丰富的可再生资源,昆虫体内含有丰富的蛋白质、油脂和人体所需要的游离氨基酸以及一些具有药用价值的活性物质,因此具有较高的开发和利用价值。此文综述了近几年对昆虫资源的研究以及开发利用现状。     

2012 年全球上市新药

对2012 年全球上市新药的基本信息,包括通用名、商品名、结构式、CAS 号、研发公司、上市国家和主要适应证进行汇总,为新药研发工作者提供参考。     

斑马鱼在新药发现中的应用

在过去20年里,斑马鱼已成为一种重要的模式脊椎动物,在发育、遗传、免疫、肿瘤和毒理等诸多研究领域中被广泛应用。近年来,斑马鱼作为活体模型越来越多地应用于某些生物学过程的药物筛选。通过斑马鱼初步筛选,在药物研发初期可确定化合物的生物学活性、毒性以及副作用等。最近的研究还发现,斑马鱼不仅用于新药筛选,还可用于药物结构的优化。本文重点介绍斑马鱼在新药发现中的应用。     

09中国新药创制关键技术国际研讨会在京举行

2009年6月4日,由中国医药科技成果转化中心、中国医药产业技术联盟、《中国医药技术经济与管理》杂志主办,GE（中国）医疗集团协办并独家赞助的“2009中国新药创制关键技术国际研讨会”,在北京好苑建国酒店召开。     

国家新药筛选中心与英国医学研究委员会技术部合作开展抗疟药物研究

2006年3月10日，英国医学研究委员会（Medical Research Council）技术部宣布与国家新药筛选中心开展一项重要的药物发现合作研究——抗疟药物研究。     

量子点在新药开发中的应用

由于具有优异的光学特性,量子点在生物医学领域内的研究和应用取得了一些有意义的进展,同时也引起了新药开发人员的兴趣.本文概述了量子点在新药开发中所具有的优势,分析了量子点在药物传输、药物筛选和药靶确证方面的潜在应用,进一步讨论了当前量子点应用于新药开发存在的问题和不足.     

Proteomics in biomarker discovery and drug development

Proteomics is a research field aiming to characterize molecular and cellular dynamics in protein expression and function on a global level. The introduction of proteomics has been greatly broadening our view and accelerating our path in various medical researches. The most significant advantage of proteomics is its ability to examine a whole proteome or sub-proteome in a single experiment so that the protein alterations corresponding to a pathological or biochemical condition at a given time can be considered in an integrated way. Proteomic technology has been extensively used to tackle a wide variety of medical subjects including biomarker discovery and drug development. By complement with other new technique advances in genomics and bioinformatics, proteomics has a great potential to make considerable contribution to biomarker identification and to revolutionize drug development process. This article provides a brief overview of the proteomic technologies and their application in biomarker discovery and drug development.     

Who will develop new antibacterial agents?

The golden age of antimicrobial drug development is a distant memory, and the likelihood of there being another seems slim. In part, this is because the pharmaceutical industry, which has now adopted an unsustainable business model, abandoned the anti-infective sector, and the pipeline is almost empty. The contribution to this crisis of national governments, health agencies and funders also merits discussion. Much of the basis for drug discovery is funded by the public sector, thereby generating intellectual property and leads for drug development that are often not pursued owing to funding gaps. In particular, the cost of testing drug efficacy in clinical trials is beyond the means of most companies and organizations. Lack of a concerted international effort to develop new antimicrobials is particularly alarming at a time when multidrug-resistant bacteria threaten all areas of human medicine globally. Here, the steps that led to this situation are retraced, and some possible solutions to the dilemma are proposed.     

Lipidomics analysis in drug discovery and development

Despite being a relatively new addition to the Omics' landscape, lipidomics is increasingly being recognized as an important tool for the identification of druggable targets and biochemical markers. In this review we present recent advances of lipid analysis in drug discovery and development. We cover current state of the art technologies which are constantly evolving to meet demands in terms of sensitivity and selectivity. A careful selection of important examples is then provided, illustrating the versatility of lipidomics analysis in the drug discovery and development process. Integration of lipidomics with other omics’, stem-cell technologies, and metabolic flux analysis will open new avenues for deciphering pathophysiological mechanisms and the discovery of novel targets and biomarkers.     

Yeast and drug discovery

Advanced genetic techniques, along with the high degree of conservation of basic cellular processes, have made the yeast Saccharomyces cerevisiae a valuable system for identification of new drug targets, target-based and non-target-based drug screening, and detailed analysis of the cellular effects of drugs. Yeast also presents a convenient system for antifungal drug discovery because it is closely related to Candida albicans, a major human pathogen. Many yeast genes remain poorly characterized, and most of the sophisticated techniques in yeast have been in widespread use less than a decade – a period shorter than the typical cycle from target identification to marketing approval for a new drug. It is likely that most of the benefits of yeast in discovery and development of therapeutic compounds have yet to be realized. Electronic Publication     

我国人口与健康状况简析

随着经济全球化格局的逐步形成,环境、生态、资源等与人类社会自身发展密切相关的因素已成为超越国界的共性课题。进入新世纪后,我国医药卫生事业面临着人口结构和疾病谱系迅速改变、公共卫生和医疗保健需求剧增、环境污染和食品安全保障等巨大挑战。在计划生育及生殖健康领域,在公共卫生与医疗网络领域,在医学研究与健康促进领域,以及在高新技术与健康产业领域,坚持科学的发展观,以最先进的科学技术研究成果为主导,推动关键技术的相互渗透及综合集成,提倡合理的生活方式已成为我国经济发展和社会进步的重要历史任务。     

现代生物学对药物发现的影响

随着后基因组时代的到来,药物发现研究领域不断涌现出一系列新思路、新技术、新方法,从而迅速推进药物发现的多元化发展。一方面,基因组学、蛋白质组学、转录组学、代谢组学、生物信息学、系统生物学等新兴学科的崛起与发展,为药物发现提供更为广泛而深刻的理论基础;另一方面,计算机辅助药物设计、高通量筛选、高内涵筛选、生物芯片、转基因和RNA干扰等高新技术的发展和完善,为药物发现提供了新的技术手段和有力工具,极大地拓宽了药物发现的途径。本文结合近年来现代生物学的研究进展,综述现代生物学对药物发现过程的影响。     

Evolving cryo-EM structural approaches for GPCR drug discovery

1. Download : Download high-res image (264KB)
2. Download : Download full-size image